Yifat S. Oren

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variants.

SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variants.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: March 14, 2026

Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.

Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 27, 2025

Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients.

Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients.

Journal: Nucleic acid therapeutics
Published: August 29, 2023

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: September 12, 2022

Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability.

Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability.

Journal: Cell reports
Published: March 05, 2022

Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.

Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 23, 2021

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 28, 2021

New approaches to genetic therapies for cystic fibrosis.

New approaches to genetic therapies for cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: October 17, 2019

Take it personally: how personal we reach when we are so different from each other?

Take it personally: how personal we reach when we are so different from each other?

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: January 23, 2019

The suppression of premature termination codons and the repair of splicing mutations in CFTR.

The suppression of premature termination codons and the repair of splicing mutations in CFTR.

Journal: Current opinion in pharmacology
Published: August 29, 2017

The unfolded protein response affects readthrough of premature termination codons.

The unfolded protein response affects readthrough of premature termination codons.

Journal: EMBO molecular medicine
Published: April 08, 2014

Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen.

Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen.

Journal: Cell stem cell
Published: July 08, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026